Which company produces furmonertinib and its corporate background?

Furmonertinib (Furmonertinib), with the trade name "Aifusa", is manufactured by Shanghai Allist Pharmaceutical Technology Co., Ltd. (Allist Pharmaceuticals) independently developed third-generation EGFRtyrosine kinase inhibitors (TKI). The drug is mainly used to treat patients with EGFR mutation-positive non-small cell lung cancer (NSCLC), especially for patients with T790M drug-resistant mutations.

Ailes Pharmaceuticals was established in2016 and is headquartered in Nantong City, Jiangsu Province. The company focuses on the research and development of tumor-targeted drugs and is committed to becoming the world's leading anti-tumor drug research and development company. Fumetinib is one of the core products of Ellis Pharmaceuticals and has independent intellectual property rights. The drug was approved for marketing by the National Medical Products Administration (NMPA) in China in March 2021, becoming the first approved third-generation EGFR-TKI in China.

During the research and development process, Alex Pharmaceuticals faced the challenge of unsatisfactory pharmacokinetics (PK) of the drug in vivo. However, the R&D team persisted in innovation and found that fumetinib can be rapidly distributed to lung tissue in the body. Although the plasma concentration is low, it has good efficacy in target tissues. This discovery broke through the conventional drug research and development ideas and laid the foundation for the successful launch of fumetinib.

In terms of internationalization, ArriVent Biopharma has reached a cooperation agreement with ArriVent Biopharma, authorizing it to develop and commercialize fumetinib in global markets outside of mainland China, Hong Kong, Macau and Taiwan. In addition, Ellis Pharmaceuticals also changed the English name of Furmonertinib from Furmonertinib to Firmonertinib in June 2024 to promote global development and international brand building.

In general, with the successful research and development of fumetinib, Ellis Pharmaceuticals has demonstrated the strength of Chinese biopharmaceutical companies in the field of innovative drug research and development. In the future, with the expansion of the international market and the continued advancement of new drug research and development, Ellis Pharmaceuticals is expected to occupy a place in the global anti-tumor drug market.

Reference link:https://www.drugs.com